Analysed CANDEL THERAPEUTICS INC (CADL:NASDAQ) News Sources
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
12-08-2026
marketbeat.com
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
12-08-2026
stocktwits.com
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
13-08-2026
stocktwits.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
10-09-2026
yahoo.com
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
30-09-2026
yahoo.com
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
30-09-2026
yahoo.com
CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
30-09-2026
stocktwits.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-10-2026
yahoo.com
What is the current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ) is $9.78.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) absolute price change since previous trading day?
The absolute price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is $-0.16.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) percentage price change since previous trading day?
The percentage price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is -1.6097%.
What is the most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is .
SEC-8K** Filing Available For CANDEL THERAPEUTICS INC (CADL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.